OBJECTIVE: To investigate the relationship between Krebs von den Lungen 6 (KL-6) and CCL18 levels and the severity and progression of systemic sclerosis (SSc)-related interstitial lung disease (ILD). METHODS: Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included. Baseline and 12-month plasma samples were analyzed by enzyme-linked immunosorbent assay to assess CCL18 and KL-6 levels. The forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLco) were measured every 3 months. Joint models were created to investigate the relationship between baseline CCL18 and KL-6 levels and the course of the FVC and DLco over 1 year according to treatment arm. RESULTS: Baseline KL-6 and CCL18 levels each correlated with the extent of radiographic fibrosis. Levels of both CCL18 and KL-6 declined significantly at 1 year. In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year. A higher baseline CCL18 level predicted progression of ILD based on the course of the FVC (P < 0.001 for CYC; P = 0.007 for MMF) and DLco (P = 0.001 for CYC; P < 0.001 for MMF) over 1 year, as well as mortality (P = 0.0008 for CYC arm only). CONCLUSION: In a rigorously conducted clinical trial for SSc-related ILD, KL-6 and CCL18 levels correlated with ILD severity and declined with immunosuppression. Patients with higher baseline KL-6 and CCL18 levels were more likely to experience disease progression despite treatment. KL-6 and CCL18 levels could be used to identify patients with a progressive ILD phenotype who may benefit from a more aggressive initial treatment approach.
OBJECTIVE: To investigate the relationship between Krebs von den Lungen 6 (KL-6) and CCL18 levels and the severity and progression of systemic sclerosis (SSc)-related interstitial lung disease (ILD). METHODS:Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included. Baseline and 12-month plasma samples were analyzed by enzyme-linked immunosorbent assay to assess CCL18 and KL-6 levels. The forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLco) were measured every 3 months. Joint models were created to investigate the relationship between baseline CCL18 and KL-6 levels and the course of the FVC and DLco over 1 year according to treatment arm. RESULTS: Baseline KL-6 and CCL18 levels each correlated with the extent of radiographic fibrosis. Levels of both CCL18 and KL-6 declined significantly at 1 year. In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year. A higher baseline CCL18 level predicted progression of ILD based on the course of the FVC (P < 0.001 for CYC; P = 0.007 for MMF) and DLco (P = 0.001 for CYC; P < 0.001 for MMF) over 1 year, as well as mortality (P = 0.0008 for CYC arm only). CONCLUSION: In a rigorously conducted clinical trial for SSc-related ILD, KL-6 and CCL18 levels correlated with ILD severity and declined with immunosuppression. Patients with higher baseline KL-6 and CCL18 levels were more likely to experience disease progression despite treatment. KL-6 and CCL18 levels could be used to identify patients with a progressive ILD phenotype who may benefit from a more aggressive initial treatment approach.
Authors: Faye N Hant; Anna Ludwicka-Bradley; He-Jing Wang; Ning Li; Robert Elashoff; Donald P Tashkin; Richard M Silver Journal: J Rheumatol Date: 2009-03-13 Impact factor: 4.666
Authors: Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Ning Li; Ellen Goldmuntz; Lynette Keyes-Elstein; Ashley Pinckney; Daniel E Furst; Philip J Clements; Dinesh Khanna; Virginia Steen; Dean E Schraufnagel; Shiva Arami; Vivien Hsu; Michael D Roth; Robert M Elashoff; Keith M Sullivan Journal: Ann Rheum Dis Date: 2018-11-08 Impact factor: 19.103
Authors: Gloria A Salazar; Masataka Kuwana; Minghua Wu; Rosa M Estrada-Y-Martin; Jun Ying; Julio Charles; Maureen D Mayes; Shervin Assassi Journal: J Rheumatol Date: 2018-07-01 Impact factor: 4.666
Authors: H G Kim; D P Tashkin; P J Clements; G Li; M S Brown; R Elashoff; D W Gjertson; F Abtin; D A Lynch; D C Strollo; J G Goldin Journal: Clin Exp Rheumatol Date: 2010-11-03 Impact factor: 4.473
Authors: Dinesh Khanna; Chi-Hong Tseng; Niloofar Farmani; Virginia Steen; Daniel E Furst; Philip J Clements; Michael D Roth; Jonathan Goldin; Robert Elashoff; James R Seibold; Rajeev Saggar; Donald P Tashkin Journal: Arthritis Rheum Date: 2011-10
Authors: Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker Journal: Ann Rheum Dis Date: 2010-06-15 Impact factor: 19.103
Authors: Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes Journal: Arthritis Res Ther Date: 2010-09-02 Impact factor: 5.156
Authors: Angelo De Lauretis; Piersante Sestini; Panagiotis Pantelidis; Rachel Hoyles; David M Hansell; Nicole S L Goh; Christopher J Zappala; Dina Visca; Toby M Maher; Christopher P Denton; Voon H Ong; David J Abraham; Peter Kelleher; Laureen Hector; Athol U Wells; Elisabetta A Renzoni Journal: J Rheumatol Date: 2013-02-01 Impact factor: 4.666
Authors: Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff Journal: Lancet Respir Med Date: 2016-07-25 Impact factor: 30.700
Authors: Elizabeth R Volkmann; Donald P Tashkin; Michael D Roth; Ning Li; Julio Charles; Maureen Mayes; Grace Kim; Jonathan Goldin; Lila Pourzand; Philip J Clements; Daniel E Furst; Dinesh Khanna; Robert M Elashoff; Shervin Assassi Journal: Semin Arthritis Rheum Date: 2020-06-16 Impact factor: 5.532
Authors: Nancy Wareing; Vishnu Mohan; Rana Taherian; Elizabeth R Volkmann; Marka A Lyons; Holly Wilhalme; Michael D Roth; Rosa M Estrada-Y-Martin; Brian Skaug; Maureen D Mayes; Donald P Tashkin; Shervin Assassi Journal: Arthritis Care Res (Hoboken) Date: 2022-03-14 Impact factor: 5.178
Authors: Oliver Distler; Shervin Assassi; Vincent Cottin; Maurizio Cutolo; Sonye K Danoff; Christopher P Denton; Jörg H W Distler; Anna-Maria Hoffmann-Vold; Sindhu R Johnson; Ulf Müller Ladner; Vanessa Smith; Elizabeth R Volkmann; Toby M Maher Journal: Eur Respir J Date: 2020-05-14 Impact factor: 16.671